XOMA Royalty Corporation Stock Price, News & Analysis

XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire Turnstone Biologics (NASDAQ: TSBX). The deal terms included $0.34 per share in cash plus one non-tradeable contingent value right (CVR).

As of the expiration date on August 7, 2025, 17,192,002 shares were validly tendered, representing approximately 74% of Turnstone's outstanding shares. Following the tender offer, XOMA Royalty merged Turnstone with its subsidiary XRA 3 Corp., making Turnstone a wholly owned subsidiary. Turnstone's shares will cease trading on Nasdaq as of August 11, 2025, and will be delisted and deregistered.

XOMA Royalty (NASDAQ: XOMA) has entered into a definitive agreement to acquire LAVA Therapeutics (NASDAQ: LVTX) in a structured deal valued at $1.16 to $1.24 per share in cash, plus a contingent value right (CVR). The CVR entitles shareholders to 75% of net proceeds from LAVA's partnered assets and potential out-licensing of unpartnered programs.

The transaction, expected to close in Q4 2025, requires at least 80% shareholder tender and includes specific closing conditions. As part of the deal, LAVA will discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome. The acquisition adds milestone and royalty economics from LAVA's gamma delta bispecific antibodies portfolio to XOMA Royalty's assets.

XOMA Royalty (NASDAQ: XOMA) has entered into a definitive merger agreement to acquire HilleVax (NASDAQ: HLVX) in a deal that values HilleVax shares at $1.95 in cash per share plus a contingent value right (CVR).

The CVR includes potential additional payments from: (1) excess cash above $102.95 million, (2) 90-100% of savings from Boston office lease obligations, and (3) 90% of proceeds from any norovirus vaccine program sales within specific timeframes. The deal has secured support from 22.9% of HilleVax stockholders, including officers and directors.

XOMA Royalty will commence a tender offer by August 18, 2025, with the acquisition expected to close in September 2025. The deal requires a majority of HilleVax shares to be tendered and maintaining a minimum cash balance at closing.

ESSA Pharma (NASDAQ: EPIX) has announced a definitive agreement to be acquired by XenoTherapeutics, with financing from XOMA Royalty Corporation (NASDAQ: XOMA). The all-cash transaction will provide EPIX shareholders with approximately $1.91 per common share, plus one non-transferable contingent value right (CVR) worth up to $0.06 per share payable within 18 months post-closing.

The transaction, expected to close in second half of 2025, requires approval from 66⅔% of ESSA shareholders and securityholders. The agreement includes a $2.5 million termination fee and customary deal-protection provisions. ESSA's board unanimously approved the transaction, with directors and senior officers, holding 2.23% of shares, agreeing to vote in favor.

[ "All-cash transaction providing immediate liquidity to shareholders", "Additional potential value through CVR of up to $0.06 per share", "Expedited cash distribution process compared to standard liquidation", "Unanimous board approval and management support with 2.23% commitment" ]

XOMA Royalty (NASDAQ:XOMA) has announced a definitive merger agreement to acquire Turnstone Biologics (NASDAQ-CM:TSBX). Under the terms of the agreement, XOMA will pay $0.34 in cash per share plus one non-transferable contingent value right (CVR) for each Turnstone share.

The acquisition will proceed through a tender offer starting by July 11, 2025, requiring a majority of outstanding shares to be tendered and meeting certain conditions including minimum cash balance requirements. Approximately 25.2% of Turnstone stockholders have already agreed to tender their shares. The merger is expected to close in August 2025.

XOMA Royalty Corporation (NASDAQ: XOMA) has announced quarterly dividend payments for its preferred stock series. For the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ: XOMAP), shareholders will receive $0.53906 per share. Holders of depositary shares of the 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ: XOMAO) will receive $0.52344 per depositary share, with each depositary share representing 1/1000 of a share. Both dividend payments are scheduled for July 15, 2025, with a record date of July 3, 2025.

XOMA Royalty Corporation (NASDAQ: XOMA) has acquired BioInvent International's future royalty and milestone rights for mezagitamab (TAK-079) in a deal worth up to $30 million. The transaction includes $20 million paid at closing and an additional $10 million contingent upon mezagitamab receiving FDA marketing approval for IgA nephropathy.

With this acquisition and its existing entitlements, XOMA will receive up to $16.25 million in milestones from Takeda and mid-single digit royalties on future mezagitamab commercial sales. Takeda is currently conducting a Phase 3 clinical trial for mezagitamab in immune thrombocytopenia (ITP) patients. The drug is a fully human IgG1 monoclonal antibody targeting CD38-expressing cells, with potential to become best-in-class in its category.

XOMA Royalty (NASDAQ: XOMA) reported strong Q1 2025 financial results with total income of $15.9 million, up from $1.5 million in Q1 2024. The company received $18.0 million in cash receipts, including $13.4 million in royalties and $4.6 million in milestones. Key achievements include the EMA's acceptance of tovorafenib's MAA, Takeda's Phase 3 trial initiation for mezagitamab, and acquisition of interest in Castle Creek's D-Fi through a $5 million investment. The company ended Q1 with $95.0 million in cash and reported net income of $2.4 million, compared to a net loss of $8.6 million in Q1 2024. XOMA continued its shareholder-focused strategy through share repurchases and pipeline advancement while maintaining strict expense control.

XOMA Royalty Corporation (NASDAQ: XOMA) announced its participation in two upcoming investor conferences. At the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025, CEO Owen Hughes and CIO Brad Sitko will lead multiple sessions. Hughes will participate in a fireside chat at 2:30 PM ET and join a panel on royalty model pros and cons at 4:00 PM ET. Sitko will discuss development-stage companies and royalty platforms at 5:00 PM ET.

Additionally, XOMA's business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025. The presentations will be accessible through XOMA's investor relations website.